News & Press Releases

Browse Our Archives

Press Release

San Antonio, TX – June 1, 2020

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

The COBRA REDUCE randomized control trial is a first-of-its-kind study designed to evaluate ultra-short DAPT in PCI patients at high bleeding risk with COBRA PzF NCS with 14-day DAPT compared to drug-eluting stents with 3 or 6 months DAPT.

Read Press Release